SINUS-24 and SINUS-52

DUPIXENT was studied in the largest CRSwNP biologics trial program to date.^1,4,a There were 724 total participants: 276 in SINUS-24 and 448 in SINUS-52. Adults (≥18 years) on background INCS^b with CRSwNP despite prior sinus surgery or prior treatment with (unless ineligible to receive or intolerant to) SCS in the past 2 years were enrolled in the clinical trials.¹

In both SINUS-24 and SINUS-52, 73% to 90% of subjects had opacification of all sinuses. Prior-surgery patients had a mean of 2.0 prior surgeries, and SCS-use patients had a mean of 1.6 SCS courses in the previous 2 years.¹

Patients with chronic rhinosinusitis without nasal polyps were not included in these trials. Rescue with SCS or surgery was allowed at investigators’ discretion. The total population of patients in SINUS-24 and SINUS-52 was unrestricted by minimum baseline blood eosinophil count.¹

^aValid as of February 2024.

^bAll patients in the placebo and DUPIXENT arms were on a background therapy of INCS, mometasone furoate nasal spray.⁴

INCS, intranasal corticosteroid; SCS, systemic corticosteroid.

view the study designs